Seroney I, Genga IO, Odhiambo FA, Kobayashi N, Adungo N, Vulule JM, Mpoke S, Songok E; International Conference on AIDS.
Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. TuPeF5423.
Centre for vector biology control &research, Kisumu, Kenya
BACKGROUND: Short course Zidovudine has been confirmed in reducing mother-to-child transmission of HIV. However there are few reports of its subsequent effects on the mother's health in absence of other antiretroviral therapy. We present observations on disease progression on mothers who had been exposed to short course Zidovudine during pregnancy in Western Kenya. METHODS: 825 pregnant mothers (216 HIV positive and 609 HIV negative) were on consent recruited in 1996 and 1998. HIV positive mothers were given short course Zidovudine (100-mg qid) beginning at 36th week of gestation till delivery, followed by 300 mg 3 hourly during labor. 120 HIV positive mothers received ZDV and 96 did not mainly because deliveries occurred earlier than expected. All mothers and children were clinically monitored and followed up for a period of two years when vertical transmission and mortality rates were analyzed. Outcome of vertical transmission and child mortality rates in this study has been reported elsewhere. Outcome: Of the 120 mothers who received Zidovudine, 16 (13.3%) has died by 24 months as compared to 17 deaths (17.7%, p= 0.5) in those who did not receive Zidovudine. Three mothers died (0.5%) from the HIV negative group. CONCLUSION: Observations within a 2 year period show that short course Zidovudine monotherapy taken during pregnancy has no influence on disease progression of the mother.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Child
- Delivery, Obstetric
- Disease Progression
- Disease Transmission, Vertical
- HIV Infections
- HIV Seropositivity
- Humans
- Kenya
- Mothers
- Observation
- Pregnancy
- Pregnancy Complications, Infectious
- Pregnancy Outcome
- Zidovudine
- methods
- surgery
- transmission
Other ID:
UI: 102259873
From Meeting Abstracts